Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$0.59 USD
0.00 (-0.78%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $0.59 0.00 (0.58%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.59 USD
0.00 (-0.78%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $0.59 0.00 (0.58%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights: Adaptimmune Therapeutics, Barnes Group, Mobile TeleSystems, JA Solar Holdings and Newtek Business Services
by Zacks Equity Research
Zacks.com featured highlights: Adaptimmune Therapeutics, Barnes Group, Mobile TeleSystems, JA Solar Holdings and Newtek Business Services
Strength Seen in Adaptimmune Therapeutics (ADAP): Stock Soars 15.2%
by Zacks Equity Research
Adaptimmune Therapeutics plc (ADAP) was a big mover last session, as the company saw its shares rise over 15% on the day.
Humana (HUM) Likely to Beat Q1 Earnings: Stock to Gain?
by Zacks Equity Research
We expect Humana Inc. (HUM) to beat expectations when it reports first-quarter 2017 results on May 3, before the market opens
Adaptimmune Therapeutics (ADAP) Jumps: Stock Rises 10.5%
by Zacks Equity Research
Adaptimmune Therapeutics plc (ADAP) shares rose over 10% in the last trading session.